Disease · MONDO_0017604
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: deaths from any cause | 61 of 201 | 65 of 202 | 403 | NCT01974440 | Trial comparisons |
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 197 of 199 | 199 of 201 | 400 | NCT01974440 | Trial comparisons |
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: serious adverse events | 76 of 199 | 113 of 201 | 400 | NCT01974440 | Trial comparisons |
| Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo: deaths from any cause | 27 of 178 | 47 of 180 | 358 | NCT01938001 | Trial comparisons |
| Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo: serious adverse events | 45 of 176 | 25 of 180 | 356 | NCT01938001 | Trial comparisons |
| Vitamin D Plus Rituximab vs Placebo Plus Rituximab: All-Cause Mortality | 4 of 135 | 3 of 71 | 206 | NCT03078855 | Trial comparisons |
| Vitamin D Plus Rituximab vs Placebo Plus Rituximab: deaths from any cause | 4 of 135 | 3 of 71 | 206 | NCT03078855 | Trial comparisons |
| Vitamin D Plus Rituximab vs Placebo Plus Rituximab: serious adverse events | 16 of 135 | 9 of 71 | 206 | NCT03078855 | Trial comparisons |
| Vitamin D Plus Rituximab vs Placebo Plus Rituximab: Number of Participants With Treatment Response at 13 Weeks | 113 of 135 | 59 of 70 | 205 | NCT03078855 | Trial comparisons |
| Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: Number of SAEs (Zandelisib When Combined With Rituximab) | 12 of 41 | 8 of 41 | 82 | NCT04745832 | Trial comparisons |
| Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: Number of Treatment Emergent AEs (Zandelisib When Combined With Rituximab) | 38 of 41 | 37 of 41 | 82 | NCT04745832 | Trial comparisons |
| Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: deaths from any cause | 1 of 41 | 1 of 41 | 82 | NCT04745832 | Trial comparisons |
| Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: serious adverse events | 12 of 41 | 8 of 41 | 82 | NCT04745832 | Trial comparisons |
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: Number of Participants With TEAEs: Participants With MZL | 28 of 28 | 28 of 28 | 56 | NCT01974440 | Trial comparisons |
| VELCADE R-CAP vs VELCADE R-CP: Number of Patients Who Experienced at Least One Serious Adverse Event | 2 of 7 | 12 of 48 | 55 | NCT00715208 | Trial comparisons |
| VELCADE R-CAP vs VELCADE R-CP: serious adverse events | 2 of 7 | 12 of 48 | 55 | NCT00715208 | Trial comparisons |
| VELCADE R-CAP vs VELCADE R-CP: Number of Participants With Overall Response (OR) | 6 of 6 | 37 of 48 | 54 | NCT00715208 | Trial comparisons |
| VELCADE R-CAP vs VELCADE R-CP: Number of Patients With Complete Response (CR) | 1 of 6 | 13 of 48 | 54 | NCT00715208 | Trial comparisons |
Arm 1, Cohort 1 Follicular Lymphoma Level 1 vs Arm 2, Cohort 2 Marginal Zone Lymphoma, Mantle Cell Lymphoma, & Chronic Lymphocytic Leukemia Level 1: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 5 of 5 | 5 of 6 | 11 | NCT04599634 | Trial comparisons |
| Arm 1, Cohort 1 Follicular Lymphoma Level 1 vs Arm 2, Cohort 2 Marginal Zone Lymphoma, Mantle Cell Lymphoma, & Chronic Lymphocytic Leukemia Level 1: deaths from any cause | 0 of 5 | 0 of 6 | 11 | NCT04599634 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0017604/comparisons